Boston Scientific (BSX)
NYSE:BSX
Want to see BSX full AI Analyst Report?
Top Page
Boston Scientific
(NYSE:BSX)
Select Model
Select Model
Rating:63Neutral
Price Target:
$69.00
▲(7.43% Upside)
Action:ReiteratedDate:04/23/26
The score is supported primarily by strong multi-year financial execution and improved profitability, plus a generally constructive (but cautious) earnings outlook. It is held back by weak technical trend signals and a high P/E valuation, alongside near-term operational and margin headwinds cited on the latest earnings call.
Positive Factors
Diversified procedure-driven portfolio
Boston Scientific's mix of disposable procedural tools and implantable systems creates recurring per-procedure revenue and follow-on replacement streams. This business model links growth to procedure volumes globally, supports predictable unit economics, and cushions revenue during cyclical swings.
Negative Factors
Elevated absolute debt load
Although leverage ratios improved, an $11.4B absolute debt stock constrains flexibility if growth softens or rates rise. Planned acquisition financing and covenanted facilities increase near-term refinancing and integration risk, potentially forcing priorization of deleveraging over growth investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified procedure-driven portfolio
Boston Scientific's mix of disposable procedural tools and implantable systems creates recurring per-procedure revenue and follow-on replacement streams. This business model links growth to procedure volumes globally, supports predictable unit economics, and cushions revenue during cyclical swings.
Read all positive factors
Boston Scientific (BSX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$89.10B
Dividend YieldN/A
Average Volume (3M)14.17M
Price to Earnings (P/E)17.4
Beta (1Y)0.78
Revenue Growth17.44%
EPS Growth74.36%
CountryUS
Employees53,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.80
Shares Outstanding1,486,175,200
10 Day Avg. Volume13,132,437
30 Day Avg. Volume14,174,107
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)5.82
Price to Sales (P/S)7.03
P/FCF Ratio38.59
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda19.42
Forecast
1Y Price Target
$90.00Price Target Upside40.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering28
EPS Forecast (FY)3.38
Revenue Forecast (FY)$21.75B
Boston Scientific Business Overview & Revenue Model
Company Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offer...
How the Company Makes Money
Boston Scientific primarily makes money by selling single-use and implantable medical devices and related accessories to healthcare providers and purchasing organizations. Revenue is largely generated when hospitals and clinics purchase consumable...
Boston Scientific Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyBoston Scientific Earnings Call Summary
Earnings Call Date:Apr 22, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 29, 2026
Earnings Call Sentiment Neutral
The call reflected a mixed picture: a strong Q1 with organic growth and EPS above guidance, meaningful product and regional momentum (notably in EP/PFA, WATCHMAN clinical data, Asia Pacific), and solid capital priorities (buyback, Penumbra deal). However, management lowered near-term guidance and flagged several material headwinds — weaker Urology, some EP share pressure, margin compression (gross margin down 100 bps) and operational disruptions (POLARx discontinuation and supply issues) — leading to a more cautious full-year outlook. The company emphasizes confidence in longer-term strategy and product pipeline while taking near-term actions to control costs and invest commercially.Positive Updates
Quarterly Revenue and Organic Growth Beat Guidance
Q1 consolidated revenue of $5.203B, reported growth +11.6% vs Q1 2025; operational/organic revenue growth +9.4%, above guidance range of 8.5%–10%.
Negative Updates
Full-Year and Q2 Guidance Reduced
Company reduced Q2 organic growth guidance to 5%–7% and lowered full-year 2026 organic growth guidance to 6.5%–8.0%, citing unanticipated headwinds and changing business patterns.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Revenue and Organic Growth Beat Guidance
Q1 consolidated revenue of $5.203B, reported growth +11.6% vs Q1 2025; operational/organic revenue growth +9.4%, above guidance range of 8.5%–10%.
Read all positive updates
Company Guidance
Boston Scientific updated 2Q and full‑year 2026 guidance: Q2 reported revenue growth 5.5%–7.5% (operational/organic 5.0%–7.0%) with Q2 adjusted EPS $0.82–$0.84; full‑year reported revenue growth 7.0%–8.5% (operational/organic 6.5%–8.0% after an assumed ~50 bp FX tailwind), full‑year adjusted EPS $3.34–$3.41 (up 9%–11% vs. 2025, including an ≈$0.04 FX headwind), and adjusted operating margin expansion of 50–75 bps (Q1 adjusted operating margin ~28%, Q1 adjusted gross margin 70.5%). They also expect full‑year free cash flow of ~$4.0 billion, a full‑year adjusted tax rate of ~12% (Q1 was 11.7%), Q1 consolidated revenue was $5.203B (11.6% reported growth including a 220 bp FX tailwind ≈$104M) and Q1 adjusted EPS was $0.80 (up 6%), the Penumbra transaction is excluded from guidance, and the Board approved a total $5B repurchase authorization with ~$2B intended to be repurchased in Q2.Boston Scientific Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
76
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.07B | 16.75B | 14.24B | 12.68B | 11.89B |
| Gross Profit | 13.85B | 10.27B | 8.83B | 7.71B | 7.46B |
| EBITDA | 3.73B | 3.94B | 3.45B | 2.74B | 2.52B |
| Net Income | 2.89B | 1.85B | 1.59B | 698.00M | 1.04B |
Balance Sheet | |||||
| Total Assets | 43.67B | 39.40B | 35.14B | 32.47B | 32.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.04B | 414.00M | 865.00M | 928.00M | 1.93B |
| Total Debt | 12.42B | 11.15B | 9.49B | 9.28B | 9.45B |
| Total Liabilities | 19.20B | 17.39B | 15.61B | 14.90B | 15.61B |
| Stockholders Equity | 24.23B | 21.77B | 19.28B | 17.57B | 16.62B |
Cash Flow | |||||
| Free Cash Flow | 3.66B | 2.65B | 1.70B | 914.00M | 1.32B |
| Operating Cash Flow | 4.53B | 3.44B | 2.50B | 1.53B | 1.87B |
| Investing Cash Flow | -2.64B | -5.69B | -2.57B | -2.01B | -1.60B |
| Financing Cash Flow | -395.00M | 1.81B | 5.00M | -548.00M | -95.00M |
Boston Scientific Technical Analysis
Negative
64.23
Price Trends
69.94
Negative
82.33
Negative
92.16
Negative
Market Momentum
-2.29
Negative
42.05
Neutral
72.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Negative. The current price of 64.23 is below the 20-day moving average (MA) of 64.81, below the 50-day MA of 69.94, and below the 200-day MA of 92.16, indicating a bearish trend. The MACD of -2.29 indicates Negative momentum. The RSI at 42.05 is Neutral, neither overbought nor oversold. The STOCH value of 72.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSX.
Boston Scientific Risk Analysis
Boston Scientific disclosed 27 risk factors in its most recent earnings report. Boston Scientific reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Boston Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $48.12B | 30.46 | 10.61% | ― | 13.81% | 22.90% | |
67 Neutral | $106.46B | 28.29 | 9.54% | 2.76% | 6.88% | 9.06% | |
66 Neutral | $126.01B | 41.38 | 15.04% | 0.95% | 11.16% | 8.08% | |
64 Neutral | $17.92B | ― | 3.97% | 1.05% | 7.20% | -20.10% | |
63 Neutral | $89.10B | 17.42 | 15.40% | ― | 17.44% | 74.36% | |
60 Neutral | $161.63B | 41.63 | 12.40% | 1.88% | 6.59% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BSX
Boston Scientific
58.45
-44.42
-43.18%
ABT
Abbott Laboratories
93.86
-34.27
-26.75%
EW
Edwards Lifesciences
82.28
6.79
8.99%
MDT
Medtronic
81.90
-0.25
-0.30%
SYK
Stryker
321.43
-48.92
-13.21%
ZBH
Zimmer Biomet Holdings
82.80
-19.18
-18.81%
Boston Scientific Corporate Events
Business Operations and StrategyProduct-Related Announcements
Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
Positive
Mar 30, 2026
On March 28, 2026, Boston Scientific announced positive results from the HI-PEITHO global randomized clinical trial showing that its EKOS Endovascular System, when used with anticoagulation, was superior to anticoagulation alone in treating patien...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Boston Scientific Secures New Credit Facilities for Acquisition
Positive
Feb 26, 2026
On February 26, 2026, Boston Scientific entered into a new $3 billion five-year revolving credit facility maturing in 2031, replacing its 2021 revolver and setting leverage covenants that allow higher temporary gearing following large acquisitions...
Business Operations and StrategyExecutive/Board ChangesStock Buyback
Boston Scientific Expands Board and Boosts Share Buybacks
Positive
Feb 23, 2026
Boston Scientific said its board on Feb. 18, 2026, expanded from 10 to 12 members and elected Starbucks chief financial officer Cathy Smith and Takeda Pharmaceutical chief executive Christophe Weber as directors, with committee assignments effecti...
Executive/Board Changes
Boston Scientific announces planned board director departure
Neutral
Feb 5, 2026
On February 2, 2026, Boston Scientific announced that long-serving director Yoshiaki Fujimori, who joined the board in July 2016 and currently chairs the Risk, Science and Technology Committee, has informed the company he will not stand for re-ele...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.